About BGI Genomics Company

As the founder of China's genetic industry, adhering to the vision of “genetic technology to benefit humanity”, the company has built a marketing service network covering more than 100 countries and all provinces, municipalities and autonomous regions of the country through more than 20 years of talent accumulation, scientific research accumulation and industrial accumulation. It has become one of the few technology companies covering the entire industry chain and application fields of the industry. It is based on advanced technology, complete configuration and leading scale multiomics production platform, and has become one of the world's leading scientific and technological service providers and precision medical service operators. The company's main business is to provide research services and comprehensive solutions for precise medical testing for scientific research institutions, enterprises, institutions, medical institutions, social health organizations, etc. through multi-omics big data technology such as genetic testing, mass spectrometry testing, and bioinformation analysis. The company's main products: Anxinke neonatal genetic disease carrier screening series, EmbryoseQ pre-implantation genetic testing series, NIFTY fetal chromosomal abnormalities non-invasive prenatal genetic testing series, multiple monogenic diseases non-invasive prenatal testing series, healthy pregnancy chromosome testing series (CNVseq), hearing hearing loss genetic testing series, anxinke neonatal genetic screening, neonatal genetic genetic screening for metabolic diseases, genetic testing series for causative genetic diseases. Corporate honors: It won the “2022 ESG Best Social Responsibility Enterprise”, “2023 Environmental, Social and Governance (ESG) Annual Case”, the 2nd “Private Enterprise Integrity and Compliance Innovation Award”, the “2023 Listed Company ESG Model Enterprise Award”, “2023 Gold Screen Award Leading Enterprise”, “2023 Carbon Dafeng Carbon Neutrality Green Development Outstanding Case”, “2023 Greater Bay Area Listed Company Annual Contribution Award”, “2023 ESG Company Green Star”, and “2023 ESG Company of the Year” and “Sunshine Industry Annual Benchmark” society Honors or awards, and has been selected for many honors such as “China Pharmaceutical Enterprise R&D Index TOP10”, “China's Top 100 ESG Listed Companies”, “2023 Top 10 Chinese Gene Technology Companies”, and “2023 Top 20 Green Governance for Listed Companies in the Greater Bay Area”.